Actelion's Annual General Meeting of Shareholders held in Basel, Switzerland
Actelion Pharmaceuticals Ltd / Actelion's Annual General Meeting of Shareholders held in Basel, Switzerland . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.
ALLSCHWIL/BASEL, SWITZERLAND - 18 April 2013 - At today's Annual General Meeting of Actelion Ltd (SIX: ATLN), held in Basel Switzerland, shareholders voted on a number of resolutions put forward by the Company's Board.
The meeting was attended by 272 shareholders. A total of 60'550'649 shares or 47.76% of the total outstanding shares were represented.
Lead by the Chairman of the Board, Jean-Pierre Garnier, the company presented a review of the company's 2012 performance. Highlights included the ongoing demand for Actelion's medicines, the success in key clinical studies, the strategic refocusing on specialty pharmaceuticals and the continuation of an 800 million share buyback program. The chairman reminded the shareholders that Actelion created significant value in the year under review and was among the top performers in the 2012 Blue Chip Index SMI at the Swiss Stock Market.
The shareholders approved the Business Report consisting of the Annual Report, the Annual Statutory Accounts and the Consolidated Accounts for the year 2012.
A proposal by the Board to appropriate available earnings from capital contribution and distribute as a dividend in the amount of CHF 1.00 per registered share was passed by shareholders.
Shareholders did not vote favorably in the consultative vote on the 2012 compensation report, with 60.24 percent against. The Chairman of the Board expressed his confidence that - based on the changes already made for 2013 and through ongoing consultation with shareholders - a remuneration system will be put in place that will find the approval of the company's owners at the next meeting.
The shareholders granted discharge to all members of the Board of Directors and of the Senior Management.
A proposal by the Board to reduce share capital by cancellation of repurchased shares was passed by the shareholders.
Actelion's shareholders re-elected Mr. Werner Henrich, Mr. Armin Kessler and Mr. Jean Malo to the Board for a term of three years.
In addition, the shareholders elected a new director, Mr. John J. Greisch, to the Board for a term of three years.
Following the AGM, Actelion's Board comprises a total of eleven members: Jean-Pierre Garnier (Chairman), Juhani Anttila, Robert Bertolini, Jean-Paul Clozel, Carl Feldbaum, John J. Greisch, Peter Gruss, Werner Henrich, Michael Jacobi, Armin Kessler and Jean Malo.
Finally, the shareholders confirmed Ernst & Young as the Company's statutory auditors for the business year 2013.
NOTES TO THE EDITOR
ABOUT MR JOHN J. GREISCH
Mr. John J. Greisch is currently President (as Executive Director) and Chief Executive Officer of Hill-Rom Holdings, Inc., a leading medical supplier of patient support systems such as hospital beds, therapeutic surfaces and stretchers. Under Mr. Greisch's leadership, Hill-Rom increased its investments in research and development, introducing new smart bed technology and new surfaces to the market as well as expanding its Singapore-based Asia-Pacific Innovation Center.
Before joining Hill-Rom, Mr. Greisch spent seven years at Baxter International, Inc. in various executive positions in corporate finance, operations and general management. From 2004-2006, he served as Chief Financial Officer and from 2006-2009 as President International Operations.
Mr Greisch earned a Bachelor's degree in Business Administration from the Miami University, US and a Master's Degree in Management (MBA equivalent) from the Northwestern University in Illinois, US
Mr. Greisch also serves on the Board of Lurie Children's Hospital in Chicago and is a past member of the Business School Advisory Board for Miami University's Farmer School of Business.
ABOUT ACTELION LTD.
Actelion Ltd is a biopharmaceutical company with its corporate headquarters in Allschwil/Basel, Switzerland. Actelion's first drug Tracleer®, an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension. Actelion markets Tracleer® through its own subsidiaries in key markets worldwide, including the United States (based in South San Francisco), the European Union, Japan, Canada, Australia and Switzerland.
Founded in late 1997 Actelion is a leading player in innovative science related to the endothelium - the single layer of cells separating every blood vessel from the blood stream. Actelion's over 2,400 employees focus on the discovery, development and marketing of innovative drugs for significant unmet medical needs. Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index SMI®).
For further information please contact:
Senior Vice President, Head of Investor Relations & Public Affairs
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
+1 650 624 69 36
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: Actelion Pharmaceuticals Ltd via Thomson Reuters ONE
--- End of Message ---
Actelion Pharmaceuticals Ltd
Gewerbestrasse 16 Allschwil Switzerland